Phlox Therapeutics Secures New Funding to Advance RNA Therapies for Genetic Cardiomyopathies
Phlox Therapeutics, a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, has successfully raised new funding to accelerate its lead program on genetic laminopathies. This round of funding adds ROM Utrecht Region to the existing syndicate of FIRST fund (managed by BGV), Amsterdam UMC Venture Holding, and Utrecht Health Seed Fund (UHSF). In addition, non-dilutive funding through Dutch Research Council (NWO) and a public-private partnership with the Hubrecht Institute - supported by Health~Holland -further bolsters Phlox’s financial resources.
Phlox is leveraging its innovative RNA technology to target multiple gene mutations that cause cardiomyopathies, further establishing itself as a key player in developing nextgeneration RNA therapies. Adinda Woelderink, Investment Manager at ROM Utrecht Region, commented on the investment: “We are excited to support Phlox Therapeutics in its groundbreaking work developing RNA therapies for cardiomyopathies. Their approach to addressing currently untreatable genetic laminopathies holds great promise, and we believe this funding will play a critical role in driving their lead program further into preclinical development.”
“The Phlox’s team is delighted to have the support of this syndicate of investors,” Prof. Eva van Rooij, Phlox’s CSO, added. “The public-private partnership with the Hubrecht Institute, combined with the additional support from Health~Holland, allows us to accelerate our preclinical work and simultaneously deepen our scientific understanding of cardiomyopathies. We are eager to move closer to clinical applications that could benefit patients with these life-threatening conditions.”
With the combined investment and non-dilutive funding, Phlox is set to further its development pipeline and continue pioneering RNA therapies that target the root causes of genetic heart diseases.
Source: Phlox Therapeutics
